|Bid||39.22 x 3000|
|Ask||39.25 x 2900|
|Day's range||39.08 - 39.35|
|52-week range||29.99 - 43.08|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||19.85|
|Earnings date||28 July 2021|
|Forward dividend & yield||1.56 (3.94%)|
|Ex-dividend date||06 May 2021|
|1y target est||42.94|
Dr. Anand Swaminathan, Emergency Medicine Physician in New Jersey, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Yahoo Finance’s Rick Newman reports vaccination disputes arising as return to work picks up steam.
Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.